Medtronic PLC has been ordered to stop making and distributing the Synchromed II implantable infusion pumps except in limited circumstances until the company corrects quality system violations in a complaint and consent decree between FDA and the firm, filed in U.S. District Court April 27.
The consent decree names the company and CEO S. Omar Ishrak and Medtronic Neuro President Thomas M. Tefft for violations...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?